Moderna's Coronavirus Vaccine to Be Reviewed by FDA Advisory Committee on Dec. 17

Brian Orelli, PhD, The Motley Fool
·2 min read
Moderna's Coronavirus Vaccine to Be Reviewed by FDA Advisory Committee on Dec. 17

Moderna (NASDAQ: MRNA) reported complete data for its coronavirus vaccine candidate, mRNA-1273, today. It also submitted its application for emergency use authorization to the Food and Drug Administration (FDA). Investors will have to wait a few weeks to see what the agency thinks of the data package.